- GSK, Theravance develop respiratory drug candidates
- GSK signs broad collaboration with Theravance
- Theravance completes $91.5mm IPO
- GSK, Exelixis co-develop, -promote therapeutics; terminated
- GSK, NeuroSearch renew CNS deal; concluded
- Evotec Neurosciences gets rights to Roche's CNS compounds; terminated
- Evotec gets Alzheimer's disease candidates from Roche; concluded
- Roche, Amira agree to inflammation drug deal
- AstraZeneca takes on Targacept's cognitive disorder candidate; deal ends
- AstraZeneca gets rights to AtheroGenics's AGI1067; terminated
- AstraZeneca to buy KuDOS for $210mm
- Trubion, Wyeth co-develop CD20-targeted drugs; deal terminated
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.